Skip to main content
Equibles
DARE logo

DARE · Dare Bioscience, Inc. · Metrics

Track DARE — free

Use DARE with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DARE.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.85 +0.01 (+0.85%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on the Company's current analysis of the conditions described above, there is substantial doubt about the Company's ability to continue as a going concern within the 12 month period from the issuance date of the accompanying condensed consolidated financial statements given that the timing and amount of potential revenue the Company may generate remain uncertain.”
View the 10-Q filed Aug 13, 2026
Market Cap
$13.29M
Shares
15.29M
Volume · Oct 5 157.18K Avg daily vol (3M) 523.88K

DARE metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.84
Market cap
$13.29M

Price action

20 metrics
Price change (1W)
+8.6%
Price change (30D)
+16.9%
Price change (3M)
-59.7%
Price change (6M)
-51.6%
Price change (YTD)
-56.3%
Price change (1Y)
-60.8%
Trailing year
Price change (5Y)
—
52-week high
$3.27
52-week low
$0.71
Change from 52-week high
-74.2%
Change from 52-week low
+19.5%
Annualized volatility
105.3%
Annualized volatility (3M)
111.1%
Beta
1.1
RSI (14D)
50.5
Price vs SMA 50
-10.1%
Price vs SMA 200
-50.9%
Avg volume (3M)
523,875
Relative volume
0.3
Average dollar volume
$535,899

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
15.29M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
9.7×
reciprocal yield 10.3%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-82.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
37.2%
Operating margin
-1,315.5%
Trailing 12 months
Net margin
-1,300.7%
Gross profit (TTM)
—
Operating profit (TTM)
−$11.11M
Net income (TTM)
−$10.99M
Trailing 12 months
Diluted EPS (TTM)
$-0.66
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.20

Growth

11 metrics
Revenue growth YoY
+10,429.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.37M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+67.8%
Year over year · more shares
Revenue CAGR (3Y)
-53.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-49.1%
Debt / equity
—
Current ratio
1.0
EBITDA (TTM)
−$8.98M
Free cash flow (TTM)
—
Quick ratio
1.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$12.62M
Total assets
$22.37M
Total debt
$10,542

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$11.29M
Capital expenditures (TTM)
$461,929
R&D (TTM)
$2.70M
SG&A (TTM)
$8.92M
Stock compensation (TTM)
$1.50M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
28
13F filer change QoQ
+2
Institutional ownership
8.5%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
48 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1401914 CUSIP 23666P200 13F (30d) 1 filings 1 filers Visit website Investor relations